The 14 references in paper P. Rumyantsev O., S. Korenev V., U. Rumyantseva V., П. Румянцев О., С. Коренев В., У. Румянцева В. (2015) “СОВРЕМЕННЫЕ ПРИНЦИПЫ ТЕРАПИИ ЛЕВОТИРОКСИНОМ ПОСЛЕ ОПЕРАЦИИ У БОЛЬНЫХ ВЫСОКОДИФФЕРЕНЦИРОВАННЫМ РАКОМ ЩИТОВИДНОЙ ЖЕЛЕЗЫ // CONTEMPORARY APPROACHES TO LEVOTHYROXINE THERAPY AFTER SURGERY IN PATIENTS WITH WELL-DIFFERENTIATED THYROID CANCER” / spz:neicon:ogsh:y:2013:i:2:p:5-8

1
Vassart G., Dumont J.E. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr Rev 1992;13(3):596–611.
(check this in PDF content)
2
Hoelting T., Tezelman S., Siperstein A.E. et al. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro. Thyroid 1995;5(1):35–40.
(check this in PDF content)
3
Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 2008;93(4):1167–9.
(check this in PDF content)
4
Pacini F. Why do we need guidelines for differentiated thyroid cancer? Thyroid 2006;16(2):103–4.
(check this in PDF content)
5
C ooper D.S., Doherty G.M., Haugen B.R. et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16(2):109–42.
(check this in PDF content)
6
Am dur R.J., Mazzaferri E.L. Essentials of thyroid cancer managenent. New-York: Springer, 2005.
(check this in PDF content)
7
Ma zzaferri E.L. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999;9(5):421–7.
(check this in PDF content)
8
Burmeister L.A., Goumaz M.O., Mariash C.N., Oppenheimer J.H. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 1992;75(2):344–50.
(check this in PDF content)
9
Sugi tani I., Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 2011;150(6):1250–7.
(check this in PDF content)
10
Bion di B., Filetti S., Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005;1(1):32–40.
(check this in PDF content)
11
Mazza ferri E.L., Kloos R.T. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86(4):1447–63.
(check this in PDF content)
12
Pujol P., Daures J.P., Nsakala N. et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81(12):4318–23.
(check this in PDF content)
13
Jonklaa s J., Sarlis N.J., Litofsky D. et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006;16(12):1229–42.
(check this in PDF content)
14
Hovens G .C., Stokkel M.P., Kievit J. et al. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007;92(7):2610–5.
(check this in PDF content)